Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Coagulation

Coagulation

Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...

Coagulation

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Vaccination in individuals with Down syndrome: immune vulnerability, safety, efficacy and opportunities.

NPJ vaccines·2026

Same author

DYRK1A and Parkinson's disease, facts and hypotheses.

Neurobiology of disease·2026

Same author

Defining a novel DYRK1A-gp130/IL-6R-pSTAT axis that regulates Th17 differentiation.

ImmunoHorizons·2025

Same author

Down syndrome: insights into autoimmune mechanisms.

Nature reviews. Rheumatology·2023

Same author

FRTX-02, a selective and potent inhibitor of DYRK1A, modulates inflammatory pathways in mouse models of psoriasis and atopic dermatitis.

Journal of translational autoimmunity·2023

Same author

Deep immune phenotyping reveals similarities between aging, Down syndrome, and autoimmunity.

Science translational medicine·2022

Same journal

Advances in Hemostasis Laboratory Testing.

Clinics in laboratory medicine·2026

Same journal

Extracellular Vesicles in Hemostasis.

Clinics in laboratory medicine·2026

Same journal

Thrombin Generation Assay: Ready for Prime Time.

Clinics in laboratory medicine·2026

Same journal

Viscoelastic Testing for the Laboratorian: Recent Advances and Practical Advice.

Clinics in laboratory medicine·2026

Same journal

Practical Recommendations for Harmonization of Hemostasis Testing Across Hospital Sites.

Clinics in laboratory medicine·2026

Same journal

The Role of Hypoxia in Vascular Endothelial Dysfunction and Venous Thromboembolism.

Clinics in laboratory medicine·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)

Published on: August 4, 2023

Laboratory evaluation of hypercoagulability.

Bernard Khor¹, Elizabeth M Van Cott

¹Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Jackson 235, 55 Fruit Street, Boston, MA 02114, USA.

Clinics in Laboratory Medicine

|August 12, 2009

Summary

This summary is machine-generated.

This review covers hypercoagulable states like Factor V Leiden and antiphospholipid antibodies, detailing their thrombotic risks and interactions. It also discusses advances in understanding these conditions and recommendations for laboratory testing.

More Related Videos

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Related Experiment Videos

Last Updated: Jun 21, 2026

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)

Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)

Published on: August 4, 2023

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Area of Science:

Hematology
Thrombosis Research
Clinical Pathology

Background:

Hypercoagulable states significantly increase the risk of venous and arterial thrombosis.
Several genetic and autoimmune conditions predispose individuals to abnormal blood clotting.

Purpose of the Study:

To review key hypercoagulable states and their associated thrombotic risks.
To discuss molecular pathogenesis, laboratory testing utility, and future directions.
To provide recommendations for laboratory testing in hypercoagulable states.

Main Methods:

Literature review and synthesis of current research on hypercoagulable states.
Analysis of incidence, thrombotic risk magnitude, and synergistic interactions.
Evaluation of molecular pathogenesis and clinical utility of laboratory tests.

Main Results:

Identified key hypercoagulable conditions including activated protein C resistance/Factor V Leiden, prothrombin G20210A, deficiencies of protein C, S, antithrombin, and antiphospholipid antibodies.
Discussed the varying thrombotic risks and synergistic effects among these conditions.
Highlighted advances in understanding molecular mechanisms and the clinical relevance of current diagnostic tests.

Conclusions:

Understanding hypercoagulable states is crucial for managing thrombosis risk.
Current laboratory testing offers valuable insights, but future targets for testing may emerge.
Evidence-based recommendations for laboratory testing aid in clinical decision-making.